Vaccines in lymphoma.
Levy
Ronald
R
Division of Oncology, Stanford University School of Medicine, CA, USA.
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D005544:Forecasting; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000276:immunology; D016233:Immunotherapy, Active; D008223:Lymphoma / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D051379:Mice; D000069283:Rituximab; D013045:Species Specificity; D016896:Treatment Outcome; D047368:Tumor Burden
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D007130:Immunoglobulin Idiotypes; D000069283:Rituximab